- Q1 2024 Zymeworks Inc Earnings Call TranscriptMay 02, 2024$9 (+2.74%)Earnings
- Q4 2023 Zymeworks Inc Earnings Call TranscriptMar 06, 2024$12.23 (+2.09%)Earnings
- Zymeworks Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 22, 2024
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Zymeworks Inc Earnings Call TranscriptNov 07, 2023$7.37 (+1.24%)Earnings
- Zymeworks Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Zymeworks Inc at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 Zymeworks Inc Earnings Call TranscriptAug 10, 2023$7.76 (+0.78%)Earnings
- Zymeworks Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Zymeworks Inc Earnings Call TranscriptMay 08, 2023$8.76 (+1.39%)Earnings
- Zymeworks Inc Investor Call TranscriptApr 18, 2023
- Zymeworks Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Zymeworks Inc Earnings Call TranscriptMar 07, 2023$7.96 (+0.13%)Earnings
- Zymeworks Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Zymeworks Inc HERIZON-BTC-01 Top-Line Results Call TranscriptDec 19, 2022
Zymeworks Inc at Barclays Global Healthcare Conference Transcript
Great. Good morning, everyone. My name is Ken Galbraith. I'm the Chair and CEO of Zymeworks. I want to thank Barclays for the opportunity to come to Miami Beach and present our story to you today. First of all, this is our forward-looking statement, as you see here. I encourage you to read it with a bigger print, and I can encourage you to go to our website and look at our SEC filings.
So trying to summarize Zymeworks one slide for you here. So our work is focused on kind of the power of multifunctional therapeutics, initially on oncology but eventually beyond.
So essentially, we work as an integrated R&D engine that is capable of generating 2 different types of multifunctional therapeutics, and then we use those as a crossover as well, but to the different platforms, which I'll talk about. First, we start on with a focus on the worst patient prognosis, like the difficult-to-treat cancers, those with the lowest 5-year overall survival rate. We focus on those indications. We find a target or a pair of targets we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)